Grape seed extract supplementation in non-alcoholic fatty liver disease

被引:2
|
作者
Ghanbari, Parisa [1 ]
Alboebadi, Roghayeh [1 ]
Bazyar, Hadi [2 ,3 ]
Raiesi, Davoud [4 ]
Zarejavid, Ahmad [5 ]
Azadbakht, Mohammad Karim [6 ]
Karimi, Mahdi [1 ]
Razmi, Hamidreza [1 ]
机构
[1] Ahvaz Jundishapur Univ Med Sci, Student Res Comm, Ahvaz, Iran
[2] Sirjan Sch Med Sci, Dept Publ Hlth, Sirjan, Iran
[3] Student Res Comm, Sirjan Sch Med Sci, Sirjan, Iran
[4] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Internal Med, Ahvaz, Iran
[5] Ahvaz Jundishapur Univ Med Sci, Clin Sci Res Inst, Nutr & Metab Dis Res Ctr, Ahvaz, Iran
[6] Sirjan Sch Med Sci, Dept Basic Sci, Sirjan, Iran
关键词
non-alcoholic fatty liver disease; oxidative stress; quality of life; grape seed extract; ANTIOXIDANT STATUS; OXIDATIVE STRESS; DOUBLE-BLIND; INCREASES; QUESTIONNAIRE; POLYPHENOLS; VALIDATION;
D O I
10.1024/0300-9831/a000805
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Despite rising non-alcoholic fatty liver disease (NAFLD) prevalence and its impact on liver health, there's a lack of studies on grape seed extract's (GSE) effect on oxidative stress and quality of life (QoL) in NAFLD patients. This study aims to fill this gap by the potential benefits of GSE in reducing oxidative stress and improving QoL. Methods: In this randomized clinical trial study, fifty patients with NAFLD were randomly assigned to receive either 2 tablets of GSE containing 250 mg of proanthocyanidins or placebo (25 participants in each group) for two months. QoL was evaluated using the SF-36 questionnaire, and oxidative stress variables (TAC, MDA, SOD, GPx, CAT, and IL-6) were measured at the beginning and end of the study. Results: Compared with the control group, the group supplemented with GSE experienced greater reductions in IL-6 and MDA (3.14 +/- 1.43 pg/ml vs. 2.80 +/- 0.31 pg/ml; 4.16 +/- 2.09 mu M vs. 4.59 +/- 1.19 mu M, p for all <0.05), as well as greater increases in TAC, SOD, and GPx levels (0.18 +/- 0.08 mM vs. -0.03 +/- 0.09 mM; 10.5 +/- 6.69 U/ml vs. 8.93 +/- 1.63 U/ml; 14.7 +/- 13.4 U/ml vs. 8.24 +/- 3.03 U/ml, p for all <0.05). Furthermore, the QoL questionnaire showed that physical limitations, general health, and total physical health were significantly improved in the GSE group compared with the placebo (17.0 +/- 42.0 vs. -12.0 +/- 37.5; 3.80 +/- 14.8 vs. -3.92 +/- 9.55; 5.08 5.26 vs. -7.01 +/- 13.7, p for all <0.05). Conclusions: GSE can be effective in improving oxidative stress and QoL in patients with NAFLD. More studies are needed to confirm the results of this study.
引用
收藏
页码:365 / 376
页数:12
相关论文
共 50 条
  • [31] The potential of flavonoids in the treatment of non-alcoholic fatty liver disease
    Van De Wier, Bregje
    Koek, Ger H.
    Bast, Aalt
    Haenen, Guido R. M. M.
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2017, 57 (04) : 834 - 855
  • [32] Effects of turmeric and chicory seed supplementation on antioxidant and inflammatory biomarkers in patients with non-alcoholic fatty liver disease (NAFLD)
    Ghaffari, Aida
    Rafraf, Maryam
    Navekar, Roya
    Asghari-Jafarabadi, Mohammad
    ADVANCES IN INTEGRATIVE MEDICINE, 2018, 5 (03) : 89 - 95
  • [33] Effects of curcumin on non-alcoholic fatty liver disease: A scientific metrogy study
    Li, Xiankuan
    Chen, Weisan
    Ren, Jiali
    Gao, Xinchen
    Zhao, Ying
    Song, Tianbao
    Fu, Kun
    Zheng, Yanchao
    Yang, Jinlong
    PHYTOMEDICINE, 2024, 123
  • [34] Blood oxidative stress related parameters in alcoholic liver disease and non-alcoholic fatty liver disease
    Das, Subir Kumar
    Balakrishnan, V.
    Mukherjee, Sukhes
    Vasudevan, D. M.
    PROCEEDINGS OF THE 3RD BIENNIAL MEETING OF THE SOCIETY FOR FREE RADICAL RESEARCH - ASIA & 6TH ANNUAL MEETING OF THE SOCIETY FOR FREE RADICAL RESEARCH - INDIA, 2007, : 11 - +
  • [35] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250
  • [36] Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease
    Tejada, Silvia
    Capo, Xavier
    Mascaro, Catalina M.
    Monserrat-Mesquida, Margalida
    Quetglas-Llabres, M. Magdalena
    Pons, Antoni
    Tur, Josep A.
    Sureda, Antoni
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (22) : 2558 - 2570
  • [37] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [38] Vitamin D supplementation and non-alcoholic fatty liver disease: A critical and systematic review of clinical trials
    Sharifi, Nasrin
    Amani, Reza
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2019, 59 (04) : 693 - 703
  • [39] Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease
    Lakhani, Hari Vishal
    Sharma, Dana
    Dodrill, Michael W.
    Nawab, Athar
    Sharma, Nitin
    Cottrill, Cameron Lee
    Shapiro, Joseph I.
    Sodhi, Komal
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2018, 15 (14): : 1591 - 1599
  • [40] Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease
    Catalina Hernandez-Rodas, Maria
    Valenzuela, Rodrigo
    Videla, Luis A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (10) : 25168 - 25198